AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06295900 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Intervention 2 Group
Description: It is planned to include 20 patients in this group and perform an aromatherapy massage with a mixture of only lavender oil (12 drops of lavender oil in 20 ml of sweet almond oil), once a day for three days, for a total of 30 minutes.
Study NCT06295900 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Group
Description: It is planned to include 20 patients in this group and perform an aromatherapy massage with only almond oil (20 ml sweet almond oil) mixture, once a day for three days, for a total of 30 minutes.
Study NCT05989724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SON-DP
Description: Solution for IV administration
Study NCT05925673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: Participants will perform exercises with their unaffected arm in front of a mirror with the affected arm hiding behind the mirror. They will watch the reflection of the unaffected arm as they perform the exercises to provide visual feedback that the affected arm is performing the exercises. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
Study NCT05925673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Stimulation (NMES)
Description: Participants will use a portable NMES machine to stimulate the wrist extensors and flexors of the affected arm at a low intensity with the arm relaxed. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
Study NCT05925673 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy + NMES
Description: Participants will perform exercises with their unaffected arm in front of a mirror with the affected arm hiding behind the mirror. They will watch the reflection of the unaffected arm as they perform the exercises to provide visual feedback that the affected arm is performing the exercises. During the exercises they will have a portable NMES machine set up to stimulate the wrist extensors and flexors of the affected arm at a low intensity with the arm relaxed. They will repeat this procedure for 10 minutes, 3 times a day, 5 days a week for 3 weeks.
Study NCT04746963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXT107 0.25 mg
Description: Single intravitreal injection of AXT107 0.25 mg/eye (mid dose)
Study NCT04746963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXT107 0.5 mg
Description: Single intravitreal injection of AXT107 0.5 mg/eye (high dose)
Study NCT06251570 — intervention group
Intervention type: OTHER
Intervention: Evaluation of Dual Task Performance
Description: The Montreal Cognitive Evaluation Scale will be used to evaluate the cognitive functions of the participants.~Evaluation of Physical Activity Level: The Turkish validity and reliability of the International Physical Activity Questionnaire Short Form made by Sağlam et al. will be used.~Evaluation of Quality of Life: It will be evaluated by the European Organization for Cancer Research and Treatments QLQ-C30 questionnaire.~Fatigue Evaluation: A fatigue severity scale consisting of 9 items will be used.~Dyspnea Assessment: The Modified Medical Research Council Dyspnea Scale will be used.~Respiratory Muscle Endurance: Evaluation will be done by respiratory muscle endurance test at constant threshold load with a Power Breathe device and according to the metronome warning and a MOXY monitor will be used. In evaluation of dual-task performance, an auditory task test will be performed while walking on the treadmill.
Study NCT05979714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-centered injection site
Description: CAB-RPV LA will be delivered in a trans-friendly injection clinic at Bridge HIV, which is centrally located in SF. The clinic is staffed by physicians, nurses, and peer navigators who are experienced working with the trans community and are experts in delivery of injectable formulations. For patients unable to attend follow-up clinic visits, arrangements will be made for a clinical provider and peer navigator to conduct a home visit for injection delivery. This implementation strategy will overcome structural barriers where it is difficult to get a visit appointment, and when appointments are missed, even harder to re-schedule. The central location in a quiet, safe and trans-affirming clinical site will make injections easy-to-access. Because the Bridge HIV clinic is not a primary care site, injections can be delivered with minimal wait times due to low patient load relative to clinical capacity.
Study NCT05979714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-centered adherence support
Description: A Trans peer navigator will support trans women living with HIV receiving long-acting injectable treatment through our delivery model. Peer navigators will reach out to trans women using our highly effective mobile SMS platform to provide additional support before and between visits. This platform provides automated weekly check-ins for streamlined support and bi-directional asynchronous texting with a peer navigator. Peer navigators will use this SMS platform to send appointment reminders, assess needs for re-scheduling, answer questions and triage concerns regarding CAB-RPV LA, and offer support for transportation or scheduling a home visit. This approach has demonstrated efficacy in improving ART adherence and viral suppression in people living with HIV as well as retention in care and adherence to PrEP.
Study NCT05979714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provider education
Description: To support effective outreach to and education of providers on novel evidence-based practices, SFDPH has utilized public health detailing (brief educational visits via a nurse practitioner) to ensure providers are prepared to implement new interventions. This strategy has been effective in expanding the implementation of PrEP, RAPID ART initiation, and comprehensive STI screening across clinics in SF. For this study, we will develop educational materials on the CAB-RPV LA regimen, including a summary of results from Phase 3 trials (ATLAS20, FLAIR21), the FDA labeling indication, and details about SFDPH's implementation of CAB-RPV LA within our safety-net system and our new delivery model. These materials will include information on which patients will be eligible for this treatment modality and eligible for referral to our new delivery model, and how to make these referrals.
Study NCT05979714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improved clinic communication strategies
Description: For SFDPH clinics, Bridge HIV providers will communicate with primary care providers through EPIC, SFDPH's electronic health record (EHR), and one of the most common EHR systems used across clinic systems in the US. For this study, secure email and/or telephone encounters within EPIC will be used to facilitate efficient referrals of TGW living with HIV from their primary providers to the Bridge HIV injection clinic and ongoing secure communication between Bridge HIV clinicians and the primary care team. For non-SFDPH clinics, communication will be via secure email or other secure communication strategies.
Study NCT05312606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aftoral Oral gel
Description: Patients will use Aftoral® Oral Gel solution for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after gel solution application).
Study NCT05312606 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unidea Chlorhexidine digluconate mouthwash 0.20%
Description: Patients will use chlorhexidine mouthwash 0,20% for the domiciliary application once a day for 15 days after the visits (no rinsing and eating for 30 minutes after mouthwash application).
Study NCT04784910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 20mg
Description: DWP14012 20mg, tablet, orally, once daily for up to 24 weeks
Study NCT04784910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole 15 mg
Description: Lansoprazole 15mg capsule, orally, once daily for up to 24 weeks
Study NCT04784910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWP14012 20mg placebo
Description: DWP14012 20mg placebo-matching tablet, orally, once daily for up to 24 weeks
Study NCT04784910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg placebo
Description: Lansoprazole 15mg placebo matching capsule, orally, once daily for up to 24 weeks
Study NCT05770921 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter
Description: All subjects will be ablated using the Pulsed Field Ablation Device and Force Sensing Pulsed Field Ablation Catheter in the management of their Paroxysmal Supraventricular Tachycardia
Study NCT05399849 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Exercises and Meditations
Description: Mindfulness exercises will be completed independently using the LoveYourBrain Foundation Meditation Library, a free, online resource containing traumatic brain injury-focused mindfulness-focused exercises and meditations. Mindfulness-based exercises and meditations to be completed will be chosen by study personnel based on tools utilized in mindfulness-based stress reduction programs that are provided on the LoveYourBrain Meditation Library. Specific mindfulness-based exercises and meditations will include body scan, acceptance, awareness, and breathing.
Study NCT04381299 — intervention group
Intervention type: OTHER
Intervention: autologous platelet rich plasma
Description: The cortex of selected ovary will be injected with 1 mL of autologous platelet rich plasma. Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
Study NCT04381299 — intervention group
Intervention type: OTHER
Intervention: saline solution
Description: The cortex of contralateral ovary will be injected with 1 mL of saline solution (SS). Up to ten different sites will be injected under ultrasound guidance. In the surgical report, the surgeon will state how many punctures have been done.
Study NCT06718998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: Participants will receive once-weekly or twice weekly NNC0519-0130 subcutaneously.
Study NCT06715098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RoboGait
Description: RoboGait: robotic-assisted gait training
Study NCT06715098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RehaWalk
Description: RehaWalk: body weight-supported treadmill training
Study NCT06715098 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Conventional: conventional walking training
Study NCT05246202 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alcohol-Anxiety Personalized Feedback Intervention 2.0
Description: AA-PFI 2.0 is a culturally adapted, brief, computer-delivered, personalized feedback intervention to address alcohol misuse in the context of clinical anxiety.
Study NCT05246202 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Personalized Feedback Intervention
Description: C-PFI is a brief, computer-delivered, personalized feedback intervention on exercise and nutrition.
Study NCT04088968 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Patients screened positive for minimun 1 SNAP factor will be offered enrollment in the study and have an individualized plan for the prehabilitation intervention.
Study NCT03874767 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Mobility
Description: A team of two mobility technicians will switch between two units on a monthly basis. The unit staffed by the mobility technician will be referred to as the intervention unit, while the other will be referred to as the control unit. One unit will start as the control unit and will switch to being the intervention unit after one month. Similarly, the other unit will start as the intervention unit and will switch to becoming the control unit after one month. All patients present on a unit during the intervention period will be provided mobility technician support according to standardized clinical guidelines that have been developed by the care team and described below. Patients who are present on a unit at the time of cross-over will not be included in the analysis, but will either no longer receive mobility technician support (if crossing from intervention to control) or will start to receive mobility technician support (if switching from control to intervention).
Study NCT06046066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NM6603
Description: NM6603 is an orally available investigational small molecule indicated for the treatment of solid malignancies including, but not limited to breast, liver, pancreatic, colorectal, cervical, melanoma and lung cancers.
Study NCT04892706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-126 Gel
Description: Gel applied to face once daily in the evening.
Study NCT04892706 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP-126 Vehicle Gel
Description: Gel applied to face once daily in the evening.
Study NCT04892706 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epiduo® Forte Gel
Description: Gel applied to face once daily in the evening.
Study NCT05157061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Galacto-oligosaccharides (GOS)
Description: An 8-week intervention study, preceded by a 2-week run-in period, in which a daily dose of a prebiotic supplement is given to adult patients diagnosed with IBS (diarrhoea, constipation or mixed-type). Patients need to report several symptom experiences and blood and faecal samples are collected.
Study NCT05157061 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrine
Description: An 8-week intervention study, preceded by a 2-week run-in period, in which a daily dose of a placebo is given to adult patients diagnosed with IBS (diarrhoea, constipation or mixed-type). Patients need to report several symptom experiences and blood and faecal samples are collected.
Study NCT05346328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Injection of A166
Description: 4.8 mg/kg for each 21 (±3) -day cycle
Study NCT06199128 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: carboxymethyl β-glucan
Description: It is a vaginal spray gel designed for the prevention and treatment of cervical lesions caused by HPV. This is achieved by controlling the physiological conditions of the transformation zone of the cervico-vaginal mucosa. The composition of the gel, which includes polycarbophil and carboxymethyl-beta-glucan, effectively shields the cervico-vaginal mucosa from the damaging effects of external agents due to its bioadhesive capacity. Additionally, it contributes to the re-epithelialization and regression of cervical lesions
Study NCT05460897 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health behaviour change
Description: weekly sessions addressing strategies to tackle behavioural risk factors for chronic disease
Study NCT05401513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Group
Description: The individuals of the Pilates group will perform specific exercises of the method, which will involve mobility, stability and muscular resistance. The exercises will progress according to the level of difficulty (basic, intermediate and advanced), load and repetition every three or four weeks.
Study NCT01053702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R475
Description: IV
Study NCT01053702 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05535309 — intervention group
Intervention type: DRUG
Intervention: cefoperazone sulbactam sodium
Description: Cefoperazone sodium and Sulbactam Sodium for injection (1; 1) are white or almost white powder drugs, and the components are cefoperazone sodium and sulbactam sodium
Study NCT06281379 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total mesogastrectomy
Description: More extended resection type with better oncological outcomes when compared to standard technique
Study NCT06281379 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total mesogastrectomy
Description: More extended resection type with better oncological outcomes when compared to standard technique
Study NCT05626244 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Being a Parent
Description: Being a Parent (BaP) is a group parenting intervention for parents of children (2-11 years old) with behavioral problems. It consists of 2-hour sessions facilitated by psychologists for between 8-12 parents. Based on attachment, family systems, and cognitive-behavioral theories, BaP successfully integrates knowledge acquisition, behavior change with adult learning and social support. Each course session is highly interactive involving an engaging blend of small and large group discussion, role play, demonstrations, information sharing and reflection. This enables parents to practice and use new skills to achieve specific goals (Day et al., 2020).
Study NCT05373212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Euglycemic clamp with BC Combo THDB0207
Description: Administration of a single dose of BC Combo THDB0207 during an euglycemic clamp procedure.
Study NCT05373212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Euglycemic clamp with Humalog® Mix25
Description: Administration of a single dose of Humalog® Mix25 during an euglycemic clamp procedure.
Study NCT06049147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBF-015 4 mg oral capsule
Description: MBF-015 oral capsules Histone deacetylase inhibitor
Study NCT06049147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBF-015 16 mg oral capsule
Description: MBF-015 oral capsules Histone deacetylase inhibitor
Study NCT04987242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALLN-346
Description: ALLN-346 (Engineered Urate Oxidase) is an orally administered, novel urate oxidase; provided as capsules for oral administration
Study NCT04987242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo capsules are similar in weight and appearance to the ALLN-346 capsules
Study NCT06049147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hard gelatin capsules filled with cellulose microcrystalline
Study NCT05953571 — intervention group
Intervention type: PROCEDURE
Intervention: Dismembered Pyeloplasty
Description: dismembered Anderson-Hynes repair was performed using 5/0 absorbable suture.
Study NCT05129787 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical resection
Description: Resection of metastasis
Study NCT05129787 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thermal ablation
Description: Ablation of metastasis
Study NCT04951102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Asthma Shared Decision-Making App
Description: The electronic Asthma SDM App will ask questions related to medicine-related, non-medicine-related, and COVID-19-related concerns about patients' asthma, the patients' personal goals for asthma control and expectation for their upcoming visit, and the patients' preferred level of details and involvement in coming to a decision about their asthma treatment. They may also use the Asthma SDM app to find information about asthma, medication management, COVID-19 and COVID-19 vaccines.
Study NCT04951102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared Decision Making Physician Training Video
Description: Training video to educate physicians on Shared Decision-Making and the use of Shared Decision-Making tools.
Study NCT04951102 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Asthma Shared Decision-Making App- Patient Data
Description: Data from the pre-visit electronic Asthma SDM app completed by the patients. Data includes medicine-related, non-medicine-related, and COVID-related concerns about patients' asthma, the patients' personal goals for asthma control and expectation for their upcoming visit, and the patients' preferred level of details and involvement in coming to a decision about their asthma treatment.
Study NCT04951102 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard Care for asthma.
Study NCT05626985 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: GAMAD
Description: Blood samples are tested for tumor markers including PIVKA-II (DCP),AFP, ctDNA methylation and biochemical tests.
Study NCT06239038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total knee arthroplasty
Description: total knee arthroplasty surgery with Police Arthroplasty joint academy center(PAJAC) Subvastus Approach
Study NCT05143333 — intervention group
Intervention type: OTHER
Intervention: DANA app
Description: The Defense Automated Neurobehavioral Assessment (DANA) is a battery of cognitive tests delivered via an electronic tablet or smartphone. The platform allows higher temporal precision and frequency of measurement than traditional neuropsychological methods while including previously standardized cognitive tests and allowing individuals to repeatedly self-administer the battery in their own homes without examiner supervision. Hence, the DANA battery bypasses several of the major limitations associated with in-person cognitive exams.
Study NCT04971967 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Crowdsourced partner services intervention
Description: The intervention includes the provision of provider referral and dual referral services, crowdsourced materials such as postcards and an HTML aiming to promote PS, as well as free take-home HIV self-testing kits.
Study NCT06438185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IRE System
Description: Irreversible Electroporation (IRE) System for Inferior Turbinate Hypertrophy with Nasal Obstruction.